Last reviewed · How we verify

NCT05398536

Kinesiophobia in Familial Mediterranean Fever

Completed Last updated 15 August 2025
What this trial tests

trial in FMF in 38 participants. Completed in 20 December 2018.

Timeline
8 January 2018
Primary endpoint
27 March 2018
20 December 2018

Quick facts

Lead sponsorHalic University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment38
Start date8 January 2018
Primary completion27 March 2018
Estimated completion20 December 2018
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Halic University

Who can join

Adults 18 to 75, any sex, with FMF. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for FMF

Currently open trials in the same condition.

Other Halic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05398536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing